An aspect of Alzheimer neuropathology after suicide transport damage
Concentrations of APP-like immunereactivity have been determined by western blotting in a soluble fraction and two membrane fractions of brain cortex from demented patients (14 with Alzheimer’s disease and 8 with other diagnoses). The concentration of APP in the soluble fraction correlated with the number of pyramidal neurones but not astrocytes or indices of interneurones. Experimental lesions in rats and quantitative autoradiography were used to investigate the cellular localisation of receptors. Lesions were produced by intrastriatal or intracortical injections of volkensin to destroy corticofugal and corticortical pyramidal neurones respectively. Volkensin treatment caused significant loss of pyramidal neurones which was accompanied by reduced binding to muscarinic cholinergic m1 receptors. [3H] 8-OH-DPAT (serotonin 1A receptors) binding was reduced only following intrastriatal volkensin. Results from the human and rat investigations are discussed in terms of the biology of cortical pyramidal neurones and drugs for the treatment of Alzheimer’s disease.
KeywordsPyramidal Neurone Amyloid Precursor Protein Cortical Pyramidal Neurone Cortical Pyramidal Cell Senile Plaque Formation
Unable to display preview. Download preview PDF.
- Blier P, Lista A, Montigny CD (1992) Differential properties of pre-and postsynaptic 5- Hydroxytryptamine1A receptors in the dorsal raphe and hippocampus. II. Effect of pertussis and cholera toxins. J Pharmacol Exp Ther 265: 16–23Google Scholar
- Clarke NA, Webster M-T, Francis PT, Procter AW, Hodgkiss AD, Bowen DM (1993) β-Amyloid precursor protein-like immunoreactivity can be altered in humans by drugs affecting neurotransmitter function. Neurodegeneration 2: 243–248Google Scholar
- Davis KL, Thai LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, Drachman DA, Schneider LS, Whitehouse PJ, Hoover TM, Morris JC, Kawas CH, Knopman DS, Earl NL, Kumar V, Doody RS (1992) A doule-blind, placebo-controlled multicenter study of tacrine for Alzheimer’s disease. N Engl J Med 327: 1253–1259PubMedCrossRefGoogle Scholar
- Francis PT, Cross AJ, Bowen DM (1994) Neurotransmitters and neuropeptides. In: Terry RD, Katzman R, Bick K (eds) Alzheimer disease. Raven Press, New York, pp 247–262Google Scholar
- Holmes C, Webster M-T, Procter AW, Francis PT, Bowen DM (1993) Relationship between P-amyloid precursor protein, pyramidal neurones and astrocytes in human neocortex. Biochem Soc Trans 21: 238SGoogle Scholar
- Sinha S, Lieberburg I (1992) Normal metabolism of the amyloid precursor protein ( APP ). Neurodegeneration 1: 169–175Google Scholar
- Webster M-T, Francis PT, Procter AW, Stratmann GC, Doshi R, Mann DMA, Bowen DM (1994) Postmortem brains reveal similar but not identical APP-like immuno- reactivity in Alzheimer compared with other dementias: implication for the novel homologue APPH. Brain Res 644: 347–351PubMedCrossRefGoogle Scholar